The firm represented Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies to treat life-threatening infections, in its $26 million IPO. Announced on August 13, the IPO was led by Cantor Fitzgerald & Co. The Sheppard Mullin team included partners Jeff Fessler, Lorna Tanner, Alex Nie and Peter Reichertz, and associates Justin Anslow, Nazia Khan, and Joy Nemirow.
Click here to read more.